RTW Institute

RTW Institute's Kinnari Patel and Da (Donny) Xu attended the Duke-Margolis Health Policy Conference, where panelists discussed U.S. biomedical innovation and AI in healthcare. RTW Institute thanks Duke-Margolis for hosting an insightful event. #DukeMargolis

Read RTW Institute's new fact sheet on the 340B program to learn about its rapid expansion and whether it benefits low-income communities: rtwinstitute.org/media/o30oexes… #340BProgram

hey all. we are looking for an executive director to lead rtw institute (our policy think tank). in addition to policy pro's, we're also interested in folks who have done healthcare equity research, consulting, or similar. also for folks interested in venture partner work, there is oppy there as well. rtwI's mission is to educate and advocate on behalf of innovation to a broad audience. it is research/data driven and nonpartisan, and looks for win win situations across a broad range of stakeholders. the rare disease and investor coalition advocating for regulatory flexibility within cber is a recent example. the ideal person is someone who can lead great research and loves to communicate, especially creatively. please dm me if you're interested, or know a friend.

Read RTW Institute's new fact sheet on Payer Barriers to learn how utilization management tools, including Prior Authorizations, affect timely treatments for patients: rtwinstitute.org/media/0oohz3o2…

Rocket Pharmaceuticals’ Head of External Affairs, Meg Dodge, LLM, highlights the benefits of the PRV program in The Butterfly Effect: How Pediatric PRVs Shape Innovation and Access to Medicines. Read more at rtwinstitute.org/policy-publica….

How can RPD PRVs create value for Biotech Stakeholders? Read The Butterfly Effect: How Pediatric PRVs Shape Innovation and Access to Medicines to learn how non-dilutive capital from PRV sales creates new opportunities for biotech stakeholders: rtwinstitute.org/policy-publica….

To date, RPD PRVs have been awarded to 71 therapies, resulting in more than $4.4 billion of non-dilutive, direct funding for drug sponsors. Read more at rtwinstitute.org/policy-publica… #RTWInstitute #PRVProgram

The RDBI Coalition published findings from a recent survey of 140+ rare disease stakeholders. Results suggest the current FDA regulatory environment is impacting rare disease investment, development activity, and patient access. Read more at rtwinstitute.org.

We are proud to announce the release of our White Paper, The Butterfly Effect: How Pediatric PRVs Shape Innovation and Access to Medicines. Learn the importance of the Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) Program at rtwinstitute.org.

The RTW Institute team traveled to D.C. to meet with Dr. Makary and his leadership to share stakeholder sentiment from the RDBI survey. We look forward to continuing an open dialogue with the FDA to support innovation and improve patient access to therapies.

Read the RTW Institute’s new fact sheet to learn about the state of antibiotic innovation on our website. #AntibioticResistance #AntibioticIncentives rtwinstitute.org/media/ezteref5…

75% of adults have never heard of a Pharmacy Benefit Manager—are you one of them? Read the RTW Institute’s new fact sheet to learn more about PBMs and how they shape the U.S. drug supply chain. rtwinstitute.org/media/cpwfnxv4…

The RDBI Coalition submitted a letter to President Trump, Secretary Kennedy, Administrator Oz, and Commissioner Makary, urging the administration to restore rare disease flexibility and innovation at the FDA. Read the full letter at: bit.ly/3PJuetS. #RareDiseaseAdvocacy

The CNPV program has the potential to be a great tool for accelerating innovation but requires more transparency and regulation. Read more at biospace.com/fda/9-months-i…).

Streamlining the IRB process matters. Innovation is the Best Medicine discusses how each day of delay carries an estimated financial cost exceeding $540,000, reflecting direct operating expenses and unrealized future revenue. endpoints.news/makary-pushes-…

RTWi CEO Kinnari Patel joined policymakers to discuss policies to support cells and gene therapy development for rare diseases. Our CEO feels optimistic about new CBER leadership and is grateful to represent the RTWi Think Tank at the White House. #FDAHealthPolicy #RareDiseases

On Tuesday, Elizabeth and Donny, joined by Joe Katakowski from the RTW Foundation, attended the inaugural #CNBCCures Summit. The summit brought together government officials, biotech industry leaders, and rare disease patient advocates. #RareDisease #HealthPolicy #PatientAdvocacy

As Rare Disease Week comes to a close, RTW Institute is sharing important statistics on rare diseases and updates on orphan drug approvals and details about the recent FDA Virtual Event for Rare Disease Day. #RareDiseaseWeek #RTWInstitute #RareDiseases #RareDiseaseMonth

In a new BioSpace article, Dr. Kinnari Patel, PharmD, MBA, CEO of RTW Institute shares her thoughts on the new Single Arm Study announced by FDA Commissioner Marty Makary. To read more, visit biospace.com/fda/fdas-one-t….

Today, RTW Institute's Policy Analysts — Elizabeth Drelichman and Donny Xu — attended the Senate Aging Committee hearing and the Rare Disease Congressional Caucus briefing hosted with the EveryLife Foundation. Thanks to EveryLife for the opportunity to participate.